Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

26.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.3K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

558
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
558
What is Genetic Engineering?00:49

What is Genetic Engineering?

76.5K
Overview
76.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
CRISPR01:59

CRISPR

53.9K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
53.9K
Gene Families01:57

Gene Families

9.4K
Gene families consist of groups of genes proposed to have originated from a common ancestor. Typically these arise through events in which a gene or genes are mistakenly duplicated during cell division. Unlike their parent genes (which are subject to selection pressure to maintain function), these gene copies do not need to preserve their sequences and may evolve at a relatively faster rate.
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
9.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a New Portable Genetic Analyzer for Point-of-Care Molecular Genetics and Pharmacogenomics Analysis.

Human mutation·2026
Same author

Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.

The pharmacogenomics journal·2026
Same author

Suicidality phenotypes reflect both shared and distinct genetic factors.

medRxiv : the preprint server for health sciences·2026
Same author

STRIPE partners in precision medicine: international perspective.

The pharmacogenomics journal·2026
Same author

From Genomes to Conversations: Outreach and Engagement in Psychiatric Genetics.

Behavior genetics·2026
Same author

Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study.

EClinicalMedicine·2026

Related Experiment Video

Updated: Nov 3, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K

Genome-based therapeutic interventions for β-type hemoglobinopathies.

Kariofyllis Karamperis1,2, Maria T Tsoumpeli3, Fotios Kounelis4

  • 1Department of Pharmacy, School of Health Sciences, Laboratory of Pharmacogenomics and Individualized Therapy, University of Patras, Patras, Greece.

Human Genomics
|June 6, 2021
PubMed
Summary

Exploring advanced treatments for severe hemoglobinopathies, this review covers pharmacogenomics, gene addition, and genome editing. These genome-based interventions offer new hope for improving patient outcomes beyond current drug and gene therapies.

Keywords:
Gene additionGene therapyGenome editing technologiesPharmacogenomicsSickle cell diseaseViral and non-viral vectorsβ-thalassemia

More Related Videos

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.9K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.2K

Related Experiment Videos

Last Updated: Nov 3, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K
CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.9K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.2K

Area of Science:

  • * Hematology
  • * Genetic Medicine
  • * Pharmacology

Background:

  • * Hemoglobinopathies, particularly severe forms, present complex challenges with existing treatments showing variable efficacy and safety.
  • * Current primary interventions like drug treatment and gene therapy offer improvements but face limitations due to disease complexity and genetic factors.
  • * Recent advancements in understanding molecular mechanisms drive innovation in therapeutic strategies.

Purpose of the Study:

  • * To provide a comprehensive overview of pharmacogenomics, gene addition, and genome editing technologies for β-type hemoglobinopathies.
  • * To elucidate the potential of these genome-based interventions as direct and indirect therapeutic strategies.
  • * To detail the latest scientific progress and achievements in managing β-type hemoglobinopathies.

Main Methods:

  • * Review of current literature on pharmacogenomics, gene addition, and genome editing.
  • * Analysis of existing drug and gene therapy approaches for β-type hemoglobinopathies.
  • * Synthesis of recent research findings and technological advancements.

Main Results:

  • * Pharmacogenomics offers personalized drug treatment strategies.
  • * Gene addition and genome editing present promising avenues for direct genetic correction or augmentation.
  • * These advanced therapies aim to overcome the limitations of current treatments and improve patient response variability.

Conclusions:

  • * Pharmacogenomics, gene addition, and genome editing represent significant advancements in treating β-type hemoglobinopathies.
  • * These genome-based interventions hold the potential to offer more effective and safer treatment options.
  • * Continued research and development are crucial for realizing the full therapeutic potential for patients.